NCOA3 and atherosclerosis: Since SRC-3 deficiency prevents atherosclerosis development, we assessed the protective effect of bufalin, a small-molecule inhibitor of SRC-3 that has been used in tumor therapy 28, 29, in the development of atherosclerosis.